About Omrix biopharmaceuticals
Omrix Biopharmaceuticals: A Pioneer in Biopharmaceuticals
Omrix Biopharmaceuticals is a leading biopharmaceutical company that specializes in developing and manufacturing innovative biological products for the healthcare industry. The company was founded in 1996 and has since then been at the forefront of research, development, and commercialization of life-saving therapies.
As a subsidiary of Johnson & Johnson, Omrix Biopharmaceuticals is part of one of the largest healthcare companies globally. With over 250 operating companies across 60 countries, Johnson & Johnson is committed to improving human health through innovation and collaboration.
Omrix Biopharmaceuticals' mission is to provide patients with safe and effective treatments for various medical conditions. The company's focus on biologics has led to the development of several groundbreaking products that have transformed patient care.
One such product is Evithrom®, a human thrombin used as an aid to hemostasis during surgical procedures. Evithrom® has been shown to be effective in reducing bleeding during surgery while minimizing adverse events associated with traditional bovine-derived thrombin products.
Another product developed by Omrix Biopharmaceuticals is FloSeal®, a hemostatic matrix used for controlling bleeding during surgery. FloSeal® combines two components - a gelatin granule component that adheres to tissue surfaces and forms an initial mechanical barrier against blood loss, followed by a thrombin component that enhances clot formation.
In addition to these products, Omrix Biopharmaceuticals also offers BioLon™ Sealant, which provides surgeons with an easy-to-use solution for sealing tissues after surgery or trauma. BioLon™ Sealant contains fibrinogen and thrombin components that work together to form clots quickly while promoting healing.
The success of Omrix Biopharmaceuticals can be attributed not only to its innovative product portfolio but also its commitment to quality assurance. The company operates under strict regulatory guidelines set forth by global health authorities such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).
Omrix Biopharmaceuticals' state-of-the-art manufacturing facilities are equipped with advanced technologies designed specifically for producing high-quality biological products safely. The company's quality control processes ensure that every batch produced meets stringent standards before being released into the market.
Moreover, Omrix Biopharmaceuticals invest heavily in research & development activities aimed at discovering new therapies for unmet medical needs. The company collaborates with academic institutions worldwide as well as other pharmaceutical companies on joint projects aimed at advancing scientific knowledge about biologics-based treatments.
In conclusion, Omrix Biopharmaceuticals stands out among other biotech firms due to its unwavering commitment towards developing innovative solutions aimed at improving patient outcomes while adhering strictly regulatory guidelines set forth by global health authorities like FDA or EMA.
With its cutting-edge technology coupled with world-class expertise from parent firm J&J; it's no wonder why this Israeli-based firm continues making waves within both local markets here domestically but also internationally too!